17042-40-9

Basic information

• Product Name: 4-METHOXYPHENYL 2,3,4,6-TETRA-O-ACETYL-ALPHA-D-MANNOPYRANOSIDE
• Synonyms: 4-METHOXYPHENYL 2,3,4,6-TETRA-O-ACETYL-ALPHA-D-MANNOPYRANOSIDE;4-Methoxyphenyl2,3,4,6-tetra-O-acetyl-a-D-mannopyranoside;4-Methoxyphenyl 2,3,4,6-Tetra-O-acetyl-α-D-mannopyranoside;4-Methoxyphenyl 2,3,4,6-tetra-O-acetyl-α-D-mannopyranoside ,98%;4-Methoxyphenyl alpha-D-mannopyranoside tetraacetate;4-Methoxyphenyl 2,3,4,6-Tetra-O-acetyl-α(2R,3R,4S,5S,6R)-2-(Acetoxymethyl)-6-(4-methoxyphenoxy)tetrahydro-2H-pyran-3,4,5-triyl triacetate;[(2R,3R,4S,5S,6R)-3,4,5-triacetyloxy-6-(4-methoxyphenoxy)oxan-2-yl]methyl acetate
• CAS NO: 17042-40-9
• Molecular Formula: C₂₁H₂₆O₁₁
• Molecular Weight: 454.42
• EINECS: 1533716-785-6
• Product Categories: Biochemistry;Glycosides;Sugars
• Mol File: 17042-40-9.mol
• Article Data: 70

Chemical Properties

• Melting Point: 102 °C
• Appearance: /
• Refractive Index: 1.523
• Storage Temp.: Freezer
• Solubility: slightly sol. in Chloroform
• CAS DataBase Reference: 4-METHOXYPHENYL 2,3,4,6-TETRA-O-ACETYL-ALPHA-D-MANNOPYRANOSIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-METHOXYPHENYL 2,3,4,6-TETRA-O-ACETYL-ALPHA-D-MANNOPYRANOSIDE(17042-40-9)
• EPA Substance Registry System: 4-METHOXYPHENYL 2,3,4,6-TETRA-O-ACETYL-ALPHA-D-MANNOPYRANOSIDE(17042-40-9)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 17042-40-9(Hazardous Substances Data)

Usage

General Description

4-Methoxyphenyl 2,3,4,6-tetra-O-acetyl-alpha-D-mannopyranoside is a complex chemical compound consisting of a methoxyphenyl group attached to a tetra-O-acetylated alpha-D-mannopyranoside molecule. 4-METHOXYPHENYL 2,3,4,6-TETRA-O-ACETYL-ALPHA-D-MANNOPYRANOSIDE is commonly used in organic chemistry and biochemistry research as a starting material or intermediate for the synthesis of various natural and synthetic compounds. Its specific properties and applications may vary depending on the context, but it generally serves as a useful building block for the creation of more complex molecules. Additionally, the acetylation of the mannopyranoside portion of the molecule can alter its reactivity and selectivity in chemical reactions, making it a valuable tool for chemical manipulation and modification.

InChI:InChI=1/C21H26O11/c1-11(22)27-10-17-18(28-12(2)23)19(29-13(3)24)20(30-14(4)25)21(32-17)31-16-8-6-15(26-5)7-9-16/h6-9,17-21H,10H2,1-5H3/t17-,18-,19+,20+,21+/m1/s1

Upstream product

• 150-76-5 4-methoxy-phenol 
• 216859-54-0 ethyl 2,3,4,6-tetra-O-acetyl-S-(N-tosylimino)-1-thio-β-D-glucopyranoside 
• 78942-85-5 2,3,4,6-tetra-O-acetyl-1-O-trifluoroacetyl-β-D-glucopyranose 
• 32934-24-0 ethyl 2,3,4,6-tetra-O-acetyl-1-thio-β-D-glucopyranoside 
• 3068-32-4 1-bromo-1-deoxy-2,3,4,6-tetra-O-acetyl-a-D-galactopyranoside 
• 70191-05-8 2,3,4,6-tetra-O-acetyl-β-D-galactopyranose 
• 3947-62-4 2,3,4,6-tetra-O-acetyl-α/β-D-galactopyranose 
• 5720-07-0 4-methoxyphenylboronic acid 
• 121238-27-5 2,3,4,6-tetra-O-acetyl-α-D-mannopyranosyl trichloroimidate 
• 42080-75-1 tris(4-methoxiphenyloxy)borane 
• 4163-65-9 per-O-acetyl-α-D-mannopyranose 
• 406946-95-0 ethyl 2,3,4,6-tetra-O-acetyl-S-(N-tosylimino)-1-thio-α-D-mannopyranoside 
• 125354-48-5 ethyl 2,3,4,6-tetra-O-acetyl-1-thio-β-D-mannopyranoside 
• 32934-24-0 S-ethyl 2,3,4,6-tetra-O-acetyl-1-deoxy-1-thio-α-D-mannopyranoside 

Downstream Products

• 105260-62-6 p-methoxyphenyl 2,3,4,6-tetra-O-acetyl-α-D-galactopyranoside 
• 1426099-68-4 C₂₇H₂₆O₉ 
• 1138123-83-7 C₄₂H₄₄Cl₃NO₁₈ 
• 1138125-17-3 C₄₂H₄₆Cl₃NO₁₈ 
• 1138125-22-0 C₄₃H₄₅Cl₃F₃NO₂₀S 
• 1138124-43-2 C₄₄H₄₈Cl₃NO₁₉ 
• 1426099-69-5 C₃₁H₃₈Cl₃N₃O₁₈ 
• 1138124-35-2 C₄₄H₄₈Cl₃NO₁₉ 
• 1426099-71-9 C₃₇H₄₂Cl₃NO₁₉ 
• 1426099-72-0 C₃₇H₄₀Cl₃NO₂₀ 
• 1426099-74-2 C₃₇H₄₁Cl₃N₂O₁₉ 
• 1593082-63-3 4-methoxyphenyl 3-O-acetyl-6-azido-2,4-diacetamido-2,4,6-trideoxy-β-D-mannopyranoside 
• 1593082-59-7 C₂₉H₂₄F₆O₁₃S₂ 
• 1593082-48-4 4-methoxyphenyl-2,4-diazido-2,4-dideoxy-3,6-di-O-benzoyl-β-D-mannopyranoside 

Relevant articles and documents

Chemical synthesis and pharmacological properties of heparin pentasaccharide analogues

The pentasaccharide fondaparinux is a synthetic anticoagulant based on heparin antithrombin-binding sequence. Fondaparinux improves safety and predictable pharmacodynamics compared with heparins; however, it requires a complicate synthesis process which contain more than 50 steps of synthesis. Herein, we designed and synthesized four fondaparinux analogues (compounds 1, 2, 3, 4) using a [2+3] convergent synthetic method, which greatly simplified the synthetic process, improved the product yield, and curtailed the expenditures. These synthesized compounds showed stronger anticoagulant activities by factor Xa inhibition (IC50 725–1126 nM vs. 1909 nM for fondaparinux) in the AT-dependent manner. After subcutaneous (s.c.) administration to rats, the compounds displayed long-lasting anti-factor Xa activities and inhibition of thrombin generation ex vivo. Compared with fondaparinux, these compounds were slowly eliminated after s.c. administration to rats, the half-lies (t1/2) were more than 2-fold of that of fondaparinux. These results suggested the pentasaccharide analogues may exhibit better pharmacokinetic and predictable pharmacodynamic characteristics.

Serendipitous one-pot synthesis of chiral dienes from pyranosidic 2,4-bistriflates

Attempted nucleophilic displacements of L-rhamnosyl 2,4-bistriflates led to serendipitous formation of a chiral diene via competing cascade eliminations. The reaction also followed the same pathway with D-rhamnosyl and D-mannosyl 2,4-bistriflates substrat

Synthesis of nature product kinsenoside analogues with anti-inflammatory activity

Kinsenoside is the major bioactive component from herbal medicine with a broad range of pharmacological functions. Goodyeroside A, an epimer of kinsenoside, remains less explored. In this report we chemically synthesized kinsenoside, goodyeroside A and their analogues with glycan variation, chirality inversion at chiral center(s), and bioisosteric replacement of lactone with lactam. Among these compounds, goodyeroside A and its mannosyl counterpart demonstrated superior anti-inflammatory efficacy. Furthermore, goodyeroside A was found to suppresses inflammatory through inhibiting NF-κB signal pathway, effectively. Structure-activity relationship is also explored for further development of more promising kinsenoside analogues as drug candidates.